行情

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

实时行情|Nasdaq Last Sale

8.03
-0.40
-4.75%
盘后: 8.03 0 0.00% 17:52 06/18 EDT
开盘
8.28
昨收
8.43
最高
8.44
最低
8.02
成交量
38.51万
成交额
--
52周最高
19.47
52周最低
6.84
市值
1.62亿
市盈率(TTM)
-5.5151
分时
5日
1月
3月
1年
5年
简报-Actinium 进一步加强了专利组合,国际知识产权涵盖了欧盟和日本 Iomab-B 抗体辐射偶联物的组成和给药方法
reuters.com · 2天前
Actinium Pharmaceuticals 的抗体辐射偶联物在欧洲和日本获得专利
MT Newswires · 2天前
Actinium 的靶向放疗实现 100% 骨髓移植
Benzinga · 4天前
BRIEF-Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment
reuters.com · 4天前
Actinium Pharmaceuticals 表示,在 2021 年 SNMMI 虚拟会议上发布的安全数据强调了接受 Lomab-B 的患者的不良事件发生率和非复发性移植相关死亡率
Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium") today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid
Benzinga · 4天前
Actinium Pharmaceuticals 在 Benzinga 全球小型企业会议上详细介绍了 SIERRA
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company that develops antibody radiation-conjugates (ARC), took part in the Benzinga Global Small Cap Business Conference on May 13, 2021.
Benzinga · 06/03 17:07
锕激活体内的辐射,用于癌细胞的目标调节
Actinium Pharmaceuticals Inc. (NYSE: ATNM), a clinical-stage biopharmaceutical company, is developing antibody radiation-conjugates (ARCs) to combine the targeting ability of antibodies with the cell-killing ability of radiation.
Benzinga · 06/03 14:00
小型生物技术公司执行最新进展,大流行后重返基本面
At the Benzinga Global Small Cap Conference Thursday, Jason McCarthy, senior managing director at Maxim Group, hosted a panel discussion on how biotech companies are getting back to fundamentals following an extremely disruptive period during the COVID-19 ...
Benzinga · 05/13 21:13
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ATNM最新的财务预测,通过ATNM每股收益,每股净资产,每股现金流等数据分析ACTINIUM PHARMAC近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ATNM价格均价为36.75,最高价位57.00,最低价为25.00。
EPS
机构持股
总机构数: 42
机构持股: 2,339.65万
持股比例: 115.85%
总股本: 2,019.49万
类型机构数股数
增持
10
554.20万
建仓
5
1,091.19万
减持
6
158.86万
平仓
5
30.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.57%
制药与医学研究
-0.98%
高管信息
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Chief Accounting Officer
Steve O'Loughlin
Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Vice President
Robert Daly
Lead Director/Independent Director
C. David Nicholson
Vice President
Steven Price
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Vice President
Vijay Reddy
Independent Director
Richard Steinhart
Vice President
Jehan Rowlands
Independent Director
C.David Nicholson
Independent Director
C. Nicholson
暂无数据
ATNM 简况
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATNM股票基本功能。